RECRUITINGINTERVENTIONAL
Studies on Adsorption International Learning Initiative Global
The Use of Sorption Technologies in Patients Receiving Program Hemodialysis With Inflammatory Syndrome
About This Trial
Use of sorption technologies in patients undergoing maintenance hemodialysis with inflammatory syndrome and clinical manifestations of uremia
Who May Be Eligible (Plain English)
Who May Qualify:
1. Adequate dialysis defined by a KT/V index ≥ 1.4
2. No active inflammatory process or infection
3. Age ≥ 18 years
4. Receiving standard hemodialysis regimen three times weekly, at least 4 hours per session
5. Participants with elevated interleukin-6 (IL-6) and/or C-reactive protein (CRP) levels exceeding local laboratory reference values
Who Should NOT Join This Trial:
1. Current use of steroids or immunosuppressive therapy
2. History of kidney transplantation
3. Diagnosis of cancer
4. Pregnancy
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
1. Adequate dialysis defined by a KT/V index ≥ 1.4
2. No active inflammatory process or infection
3. Age ≥ 18 years
4. Receiving standard hemodialysis regimen three times weekly, at least 4 hours per session
5. Participants with elevated interleukin-6 (IL-6) and/or C-reactive protein (CRP) levels exceeding local laboratory reference values
Exclusion Criteria:
1. Current use of steroids or immunosuppressive therapy
2. History of kidney transplantation
3. Diagnosis of cancer
4. Pregnancy
Treatments Being Tested
DEVICE
Patients will undergo a combined hemodialysis and hemosorption procedure. The study cartridge for hemosorption by Jafron HA130 contains the original adsorbing material.
The test cartridge will be used in addition to the ongoing program hemodialysis three times a week in the first month, twice a week in the next month, once a week in the third month
Locations (1)
Botkin Hospital
Moscow, Russia